NCT04493918

Brief Summary

This study evaluates the effectiveness of locally implantation of mesenchymal stem cell on vertebral bone defects due to infection of mycobacterium tuberculosis. there are controlled participants who receives placebo and patients who receives implantation of MSc

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started May 2017

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 21, 2017

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 30, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
Last Updated

August 3, 2020

Status Verified

July 1, 2020

Enrollment Period

3.6 years

First QC Date

July 28, 2020

Last Update Submit

July 30, 2020

Conditions

Keywords

Mycobacterium tuberculosis

Outcome Measures

Primary Outcomes (1)

  • Vertebral bony fusion

    trabecular bone on xray and CT scan

    1 Year

Study Arms (1)

MSC Group

EXPERIMENTAL

Mesenchymal Stem Cell + NaCl 0,9% 2ml

Combination Product: Mesenchymal Stem cell + Nacl 0.9%Combination Product: NaCl 0.9%

Interventions

Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit

MSC Group
NaCl 0.9%COMBINATION_PRODUCT

Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml

MSC Group

Eligibility Criteria

Age15 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Clinicoradiologically diagnoses Spinal Tuberculosis
  • receives Anti TB drugs
  • minimun destruction 1/3 vertebral body

You may not qualify if:

  • patient under 15 years old
  • reject to be included in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cipto Mangunkusumo Hospital

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

RECRUITING

MeSH Terms

Conditions

Tuberculosis, Spinal

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Tuberculosis, OsteoarticularTuberculosis, ExtrapulmonaryTuberculosisMycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsBone Diseases, InfectiousBone DiseasesMusculoskeletal DiseasesSpondylitisSpinal Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Central Study Contacts

Ahmad Jabir Rahyussalim, PhD

CONTACT

Tri Kurniawati, Mrs

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Masking Details
Participants do not know which treatment they receives. Outcome assessor is a radiologist
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr. dr. Rahyussalim SpOT(K)

Study Record Dates

First Submitted

July 28, 2020

First Posted

July 30, 2020

Study Start

May 21, 2017

Primary Completion

December 30, 2020

Study Completion

December 30, 2020

Last Updated

August 3, 2020

Record last verified: 2020-07

Locations